Brandon Hants - 27 Dec 2023 Form 4 Insider Report for Applied Molecular Transport Inc.

Reporting relationship: CFO
Issuer ticker: N/A
Reported as of: 27 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Dec 2023, 17:31:33 UTC
Prior SEC filing: 28 Dec 2023
Next SEC filing: 08 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Brandon Hants

Filing notes and source

Key filing fact

Brandon Hants filed Form 4 for Applied Molecular Transport Inc. on 28 Dec 2023.

Key facts

This page summarizes Brandon Hants's Form 4 filing for Applied Molecular Transport Inc..
8 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 28 Dec 2023, 17:31.

Change

Previous filing in this sequence was filed on 28 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMTI transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -301,225
Change %: -100%
Price
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMTI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -150,672
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,672
Exercise price: $2.38
Footnotes: F3

AMTI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -4,328
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,328
Exercise price: $4.61
Footnotes: F3

AMTI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -20,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $14.00
Footnotes: F3

AMTI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -76,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 76,000
Exercise price: $56.61
Footnotes: F3

AMTI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -57,400
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 57,400
Exercise price: $8.29
Footnotes: F3

AMTI transaction Derivative

Stock Option (RIght to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -35,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $3.99
Footnotes: F3

AMTI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -50,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.3639
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Brandon Hants is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration").

Footnote F2

Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 40,094 shares of Cyclo common stock.

Footnote F3

Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.

Footnote F4

Pursuant to the Merger Agreement, this option was exchanged for an option covering 6,655 shares of Cyclo Common Stock.